Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
Summary
Linked Publications (2)
-
Nicotine receptor partial agonists for smoking cessation.
-
Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Cotinine Level |
257.9; 258.6; 176.0; 252.1; 147.0; 264.6 | — |
| PRIMARY Change From Baseline in Cognitive Performance |
-0.19; 1.97; 3.03; 4.08; 2.49; 4.33 | — |
| SECONDARY Change From Baseline in Psychiatric Symptoms |
-3.56; -0.86; -3.05; -0.97; -0.67; 0.23 | — |
| SECONDARY Change From Basellne in Calgary Depression Scale Score |
-0.63; -0.72; -0.79; -0.88 | — |
Eligibility Criteria
Inclusion Criteria
Diagnosis of Schizophrenia or Schizoaffective Disorder Current Cigarette Smoker or History of Chronic Cigarette smoking Age 18-65 Currently taking antipsychotic medication
Exclusion Criteria
prior history of hospitalization for acute myocardial infarction or stroke, or persistent angina pectoris with current symptoms Patients who have previously tried varenicline and have stopped taking it because of side-effects of severe nausea or vomiting suicide attempt in the last year and or have had prominent or serious suicidal thoughts in the past year Women who are pregnant, nursing, or unable to use reliable contraception significant renal impairment(Creatinine ≥ 1.5) baseline Hamilton Depression Scores is >20
Data sourced from ClinicalTrials.gov (NCT00802919) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.